TEVAのチャート
TEVAの企業情報
| symbol | TEVA |
|---|---|
| 会社名 | Teva Pharmaceutical Industries Ltd （テバ・ファ―マス―ティカル・インダストリ―ズ） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | テバ・ファーマシューティカル・インダストリーズ（Teva Pharmaceutical Industries Ltd）はイスラエルの製薬会社。同社はすべての治療カテゴリー内のジェネリック医薬品の開発、生産及びマーケティングに従事する。同社の医薬品事業は「Copaxone」及び「Azilect」等主要製品を含む。同社の原薬（API）事業は自社の薬品生産に垂直統合型業務を提供する。同社のグローバル運営事業は北米・中南米からヨーロッパとアジアまでに展開される。同社はカナダ、クロアチア、チェコ、フランス、ドイツ、ハンガリー、アイルランド、イスラエル、日本、ポーランド、ロシア、スペイン、オランダ、英国と米国など国々で数多くの子会社を運営する。 テバ・ファ―マシュ―ティカル・インダストリ―ズはイスラエルの製薬会社。錠剤、カプセル、軟膏、液体、注射剤型など各種投薬形態のジェネリック医薬品(後発医薬品)を開発、製造。多発性硬化症の｢コパクソン｣、パ―キンソン病の｢アジレクト｣などブランド医薬品も製造。北米、欧州、中南米、アジア、イスラエルに製薬工場40カ所を運営。 Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. |
| 本社所在地 | 5 Basel Street Petach Tikva 4951033 ISR |
| 代表者氏名 | Sol J. Barer |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +972 3-926-7267 |
| 設立年月日 | 16103 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 42535人 |
| url | www.tevapharm.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | （百万ドル） 5002.00000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | （百万ドル） 16526.01000 |
| 売上高 | （百万ドル） 18854.00000 |
| 企業価値(EV) | （百万ドル） 43651.01000 |
| 当期純利益 | （百万ドル） -2302.00000 |
| 決算概要 | BRIEF: For the fiscal year ended 31 December 2018 Teva Pharmaceutical Industries Ltd (ADR) revenues decreased 16% to $18.85B. Net loss applicable to common stockholders excluding extraordinary items decreased 87% to $2.3B. Revenues reflect North America-North America segment decrease of 23% to $9.3B International Markets-International Markets segment decrease of 11% to $3.01B Europe-Europe segment decrease of 5% to $5.19B. |
TEVAのテクニカル分析
TEVAのニュース
Teva Pharmaceutical Industries Limited 2022 Q4 - Results - Earnings Call Presentation 2023/03/02 18:13:05 Seeking Alpha
The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with their 2022 Q4 earnings call.
Teva prices upsized $2.49B sustainability-linked senior notes offering 2023/03/02 11:15:02 Seeking Alpha
Teva Pharmaceutical Industries (TEVA) has priced upsized offering of approximately $2.49B (from $2.06B) of its sustainability-linked senior notes.The company also increased the…
Teva to raise $2.06B in sustainability-linked senior notes offering, launches $2.25B in debt tender offers for notes 2023/02/27 10:18:21 Seeking Alpha
Teva Pharmaceutical (TEVA) plans to issue $2.06B of sustainability-linked senior notes under its sustainability-linked financing framework established in October 2021, as updated in…
Teva to Present New Data from CONNECT2 Study on its Digihaler System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting 2023/02/24 13:00:00 Wallstreet:Online
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that new data on its Digihaler System will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting, being held February 24-27 in San Antonio, Texas. The data includes findings from the CONNECT2 clinical trial program as well as
Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting 2023/02/24 13:00:00 Teva Pharmaceutical Industries
Real-world insights fueled by Digihaler technology and utility of its data in patients with asthma Digihaler is the first and only smart inhaler system that can provide objective data to help patients and their doctors better support asthma management Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that new data on its Digihaler System will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting, being held February 24-27 in San Antonio, Texas. The data includes findings from the CONNECT2 clinical trial program as well as information on patients and healthcare professionals'' real-world use of the smart inhaler system. The Digihaler System is the first and only smart inhaler system with built-in sensors that provide objective inhaler event data to help patients and their doctors support asthma management and develop personalized treatment plans. The data will be
Teva to raise $2.06B in sustainability-linked senior notes offering, launches $2.25B in debt tender offers for notes 2023/02/27 10:18:21 Seeking Alpha
Teva Pharmaceutical (TEVA) plans to issue $2.06B of sustainability-linked senior notes under its sustainability-linked financing framework established in October 2021, as updated in…
Teva to Present New Data from CONNECT2 Study on its Digihaler System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting 2023/02/24 13:00:00 Wallstreet:Online
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that new data on its Digihaler System will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting, being held February 24-27 in San Antonio, Texas. The data includes findings from the CONNECT2 clinical trial program as well as
Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting 2023/02/24 13:00:00 Teva Pharmaceutical Industries
Real-world insights fueled by Digihaler technology and utility of its data in patients with asthma Digihaler is the first and only smart inhaler system that can provide objective data to help patients and their doctors better support asthma management Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that new data on its Digihaler System will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting, being held February 24-27 in San Antonio, Texas. The data includes findings from the CONNECT2 clinical trial program as well as information on patients and healthcare professionals'' real-world use of the smart inhaler system. The Digihaler System is the first and only smart inhaler system with built-in sensors that provide objective inhaler event data to help patients and their doctors support asthma management and develop personalized treatment plans. The data will be
Teva Pharma Reports Publication of New Clinician Scale to Assess the Impact of Tardive Dyskinesia on Patients Lives 2023/02/23 13:09:01 Investing.com
https://www.investing.com/news/assorted/teva-pharma-reports-publication-of-new-clinician-scale-to-assess-the-impact-of-tardive-dyskinesia-on-patients-lives-432SI-3012247
Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives 2023/02/23 13:00:00 Teva Pharmaceutical Industries
First-of-its-kind scale provides a standardized method for healthcare providers to measure tardive dyskinesia (TD) burden beyond movement severity Developed in partnership with the TD community, this scale incorporates insights from patients, caregivers and providers Offers the potential to more accurately monitor disease progression and help improve overall TD treatment and care Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the print publication of the IMPACT-TD Scale, an easy-to-use, standardized and clinician-rated assessment. The scale, developed by a consensus panel, will assist healthcare providers in determining the impact of tardive dyskinesia (TD) on different aspects of a patient’s daily functioning. IMPACT-TD categorizes the consequences of TD symptoms into multiple functional domains: social, psychological/psychiatric, physical and vocational/educational/recreational. The scale was developed to collect
Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market to Witness Huge Growth by Key Players: Novartis, Pfizer, Fresenius Kabi, Teva Pharmaceuticals, Sun Pharma 2022/11/30 08:22:34 OpenPR
ReportsnReports publishes the report titled Gastroenteropancreatic Neuroendocrine Tumor Therapeutics that presents a 360-degree overview of the market under one roof. The report is developed with the meticulous efforts of an enthusiastic and experienced team of experts, analyts, and researchers that
Marksans Pharma Limited Q2 FY23 Earnings Conference Call Insights | AlphaStreet 2022/11/25 14:19:03 AlphaStreet
Key highlights from Marksans Pharma Limited (MARKSANS) Q2 FY23 Earnings Concall Q&A Highlights: [00:12:45] Madhav Shastri asked about the new acquisition made of Teva Pharma, and the expected capex on the facility. Mark Saldanha MD clarified that the amount the company plans to spend including the acquisition cost and capex is INR200 crore. [00:13:36] Madhav
Teva Pharma PT Lowered to $7 at Piper Sandler 2022/11/23 12:37:09 Investing.com
https://www.investing.com/news/pro/teva-pharma-pt-lowered-to-7-at-piper-sandler-432SI-2950779
AbbVie Finalizes To Pay Around $2.4B In Settlement Against US Opioid Lawsuits 2022/11/22 20:01:42 Benzinga
Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) and AbbVie Inc (NYSE: ABBV ) have finalized the settlement''s terms worth over $6.6 billion to resolve several lawsuits by U.S. state and local governments over the marketing of opioid painkillers. Under the deals, first announced in July, Teva will pay up to $4.25 billion, including a supply of the overdose drug naloxone. AbbVie will pay up to $2.37 billion. Reuters reported that … Full story available on Benzinga.com
CORRECTED (OFFICIAL) -FOCUS-Generic drugmakers Teva and Sandoz make major push to biosimilars 2022/11/22 19:40:56 National Post
Generic drug makers Teva Pharmaceutical Industries and Sandoz say they are planning a significant ramp-up in production of biosimilars – copies of high-priced drugs used to treat illnesses such as rheumatoid arthritis and cancer – aiming to increase their share of an expanding market. More than 55 brand-name blockbuster biologic drugs, each with peak annual […]